Edited by Roger J. ColbranIncreasing lines of evidence support the causal link between ␣-synuclein (␣-syn) accumulation in the brain and Parkinson's disease (PD) pathogenesis. Therefore, lowering ␣-syn protein levels may represent a viable therapeutic strategy for the treatment of PD and related disorders. We recently described a novel selective ␣-syn degradation pathway, catalyzed by the activity of the Polo-like kinase 2 (PLK2), capable of reducing ␣-syn protein expression and suppressing its toxicity in vivo. However, the exact molecular mechanisms underlying this degradation route remain elusive. In the present study we report that among PLK family members, PLK3 is also able to catalyze ␣-syn phosphorylation and degradation in living cells. Using pharmacological and genetic approaches, we confirmed the implication of the macroautophagy on PLK2-mediated ␣-syn turnover, and our observations suggest a concomitant co-degradation of these two proteins. Moreover, we showed that the N-terminal region of ␣-syn is important for PLK2-mediated ␣-syn phosphorylation and degradation and is implicated in the physical interaction between the two proteins. We also demonstrated that PLK2 polyubiquitination is important for PLK2⅐␣-syn protein complex degradation, and we hypothesize that this post-translational modification may act as a signal for the selective recognition by the macroautophagy machinery. Finally, we observed that the PD-linked mutation E46K enhances PLK2-mediated ␣-syn degradation, suggesting that this mutated form is a bona fide substrate of this degradation pathway. In conclusion, our study provides a detailed description of the new degradation route of ␣-syn and offers new opportunities for the development of therapeutic strategies aiming to reduce ␣-syn protein accumulation and toxicity. Parkinson's disease (PD)2 is a neurodegenerative disorder characterized by the progressive loss of vulnerable neuronal populations in the brain and the accumulation of proteinaceous intraneuronal inclusions called Lewy bodies (1, 2). These inclusions mainly consist of a presynaptic protein, ␣-synuclein (␣-syn) (3-5). Converging lines of evidence from neuropathological studies and experimental models support the central role of ␣-syn aggregation and toxicity in the pathogenesis of PD (3, 6). This ␣-syn abnormal accumulation is in part triggered by its gene duplications/triplications or by the impairment of its degradation (3, 6). Therefore, enhancing ␣-syn elimination may represent a viable therapeutic strategy for the treatment of PD and related disorders.However, the question on how ␣-syn is eliminated in vivo has yielded controversial results (7). Although some studies reported specific elimination of the monomeric and fibrillar ␣-syn forms by the ubiquitin-proteasome system (8 -10), others reported the degradation of this protein via the autophagy-lysosomal pathway, notably the chaperone-mediated autophagy (10 -12). This controversy and the lack of known selective routes for ␣-syn elimination precluded the development ...
Since their discovery, Rho GTPases have emerged as key regulators of cytoskeletal dynamics. In humans, there are 20 Rho GTPases and more than 150 regulators that belong to the RhoGEF, RhoGAP, and RhoGDI families. Throughout development, Rho GTPases choregraph a plethora of cellular processes essential for cellular migration, cell–cell junctions, and cell polarity assembly. Rho GTPases are also significant mediators of cancer cell invasion. Nevertheless, to date only a few molecules from these intricate signaling networks have been studied in depth, which has prevented appreciation for the full scope of Rho GTPases’ biological functions. Given the large complexity involved, system level studies are required to fully grasp the extent of their biological roles and regulation. Recently, several groups have tackled this challenge by using proteomic approaches to map the full repertoire of Rho GTPases and Rho regulators protein interactions. These studies have provided in-depth understanding of Rho regulators specificity and have contributed to expand Rho GTPases’ effector portfolio. Additionally, new roles for understudied family members were unraveled using high throughput screening strategies using cell culture models and mouse embryos. In this review, we highlight theses latest large-scale efforts, and we discuss the emerging opportunities that may lead to the next wave of discoveries.
Neurodegenerative disorders refer to a group of diseases commonly associated with abnormal protein accumulation and aggregation in the central nervous system. However, the exact role of protein aggregation in the pathophysiology of these disorders remains unclear. This gap in knowledge is due to the lack of experimental models that allow for the spatiotemporal control of protein aggregation, and the investigation of early dynamic events associated with inclusion formation. Here, we report on the development of a light-inducible protein aggregation (LIPA) system that enables spatiotemporal control of α-synuclein (α-syn) aggregation into insoluble deposits called Lewy bodies (LBs), the pathological hallmark of Parkinson disease (PD) and other proteinopathies. We demonstrate that LIPA-α-syn inclusions mimic key biochemical, biophysical, and ultrastructural features of authentic LBs observed in PD-diseased brains. In vivo, LIPA-α-syn aggregates compromise nigrostriatal transmission, induce neurodegeneration and PD-like motor impairments. Collectively, our findings provide a new tool for the generation, visualization, and dissection of the role of α-syn aggregation in PD.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.